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Abstract
The aim of this study was to evaluate the effect of an antiangiogenic treatment with the vascular endothelial
growth factor antibody bevacizumab in an experimental model of breast cancer bone metastasis and to monitor
osteolysis, soft tissue tumor, and angiogenesis in bone metastasis noninvasively by volumetric computed tomog-
raphy (VCT) and magnetic resonance imaging (MRI). After inoculation of MDA-MB-231 human breast cancer cells
into nude rats, bone metastasis was monitored with contrast-enhanced VCT and MRI from day 30 to day 70 after
tumor cell inoculation, respectively. Thereby, animals of the treatment group (10 mg/kg bevacizumab IV weekly,
n = 15) were compared with sham-treated animals (n = 17). Treatment with bevacizumab resulted in a significant
difference versus control in osteolytic as well as soft tissue lesion sizes (days 50 to 70 and 40 to 70 after tumor cell
inoculation, respectively; P < .05). This observation was paralleled with significantly reduced vascularization in the
treatment group as shown by reduced increase in relative signal intensity in dynamic contrast-enhanced MRI from
days 40 to 70 (P < .05). Contrast-enhanced VCT and histology confirmed decreased angiogenesis as well as new
bone formation after application of bevacizumab. In conclusion, bevacizumab significantly inhibited osteolysis, sur-
rounding soft tissue tumor growth, and angiogenesis in an experimental model of breast cancer bone metastasis
as visualized by VCT and MRI.
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Introduction
Bone metastasis is a frequent complication of breast and prostate ma-
lignancies, which are among the most common carcinomas in women
and men. Compared with patients with other generalized neoplasias,
patients with breast cancer bone metastasis experience a relatively long
median survival time of 20 months after diagnosis of skeletal involve-
ment [1]. Because skeletal complications including pathologic frac-
tures, hypercalcemia, and bone pain in these patients can be severe,
new treatment options that expand the therapeutic arsenal beyond cur-
rently available options are desirable.
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A promising target is cancer-related angiogenesis, which is also re-
quired in bone metastasis as the tumor grows beyond a certain size
[2]. In line with this, angiogenesis was observed in bone marrow of
patients with breast cancer and was associated with progression or
recurrence of disease [3]. However, angiogenesis and antiangiogenic
treatment have not been studied systematically in breast cancer bone
metastasis. Furthermore, no animal model of breast cancer bone me-
tastasis has been described that allows one to follow angiogenesis
noninvasively in vivo.
Angiogenesis is an essential feature of cancer growth and an in-
creasing number of factors are known to be involved. Among these,
vascular endothelial growth factor (VEGF) and its isotypes play a
crucial role [4]. Interestingly, serum levels of VEGF in patients with
breast cancer were significantly increased in patients with bone me-
tastases but not in those with localized disease [5]. In experimental
models of breast cancer bone metastasis, VEGF was found to be as-
sociated with expression of bone-resorption stimulators and, conse-
quently, osteoclast-mediated osteolysis [6].
However, because skeletal lesions caused by tumor growth are rel-
atively late events in the pathogenesis of bone metastasis the moni-
toring of soft tissue–associated processes preceding bone destruction
is desirable. These processes include, for example, angiogenesis in
bone metastasis, which has not been visualized before. So far, for
imaging of tumor angiogenesis in breast and liver lesions, dynamic
contrast-enhanced (DCE) magnetic resonance imaging (MRI) is
being used in patients with cancer and has become the standard im-
aging technique [7]. In tumors, DCE MRI can noninvasively assess
vascularization and evaluate the drug efficacy of antiangiogenic
agents [7]. For small-animal research, contrast-enhanced volumetric
computed tomography (VCT) has been developed as a fast and high-
resolution imaging of new vessel formation in tumors [8,9].
The aim of this study was to combine these approaches by evalu-
ating the effect of an antiangiogenic treatment with an antibody
against VEGF and by imaging noninvasively the treatment effects
on osteolysis, surrounding soft tissue tumor, and angiogenesis in a
preclinical model of breast cancer bone metastasis in nude rats.
Materials and Methods
Cell Lines and Culture Conditions
The human estrogen-independent breast cancer cell line MDA-MB-
231 was obtained from the American Type Culture Collection. MDA-
MB-231 cells stably transfected with green fluorescent protein (GFP)
(pEGFP-N1; Clontech, Mountain View, CA) were kindly provided by
Dr. Danny R. Welch (Pennsylvania State University College of Medi-
cine, Hershey, PA). Tumor cells were cultured routinely in RPMI 1640
(Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf
serum (Sigma, Taufkirchen, Germany). All cultures were kept under
standard conditions (37°C, humidified atmosphere, 5% CO2) and pas-
saged two to three times a week to keep them in logarithmic growth.
Animals and Husbandry
Nude rats (RNU strain) were obtained from Harlan Winkelmann
(Borchen, Germany) at an age of 6 to 8 weeks. They were housed
two per cage at specific pathogen-free conditions in a minibarrier sys-
tem of the central animal facility. Autoclaved feed and water were given
ad libitum to the animals that were maintained under controlled con-
ditions (21 ± 2°C room temperature, 60% humidity, and 12-hour
light-dark rhythm). Experiments were approved by the responsi-
ble governmental animal ethics committee (Regierungspräsidium
Karlsruhe, Germany).
In Vivo Metastasis Model
Subconfluent MDA-MB-231 tumor cells were harvested using
2 mM EDTA in PBS− (phosphate-buffered saline without Ca2+
and Mg2+) and 0.25% trypsin (Sigma, Taufkirchen, Germany). Cells
were counted in a Neubauer’s chamber and suspended in RPMI
1640 (5 × 105 cells in 1 ml). For tumor cell implantation, rats
were anesthetized with a mixture of nitrous oxide (1 l/min), oxygen
(0.5 l/min), and isoflurane (1 to 1.5 vol %). For tumor cell inocula-
tion (method of inoculation described in Ref. [10]) the arterial
branches of the right hind leg were dissected. A needle was inserted
into the superficial epigastric artery, which is branching off the fem-
oral artery, and 105 MDA-MB-231 cells suspended in 0.2 ml RPMI
1640 were injected. Vessel clips were used to direct the tumor cells to
the descending genicular and popliteal arteries, which supply the
knee joint and the muscles of the leg. Resulting bone metastases were
observed exclusively in the femur, tibia, and fibula of the respective
hind leg [10].
In Vivo Imaging
For in vivo imaging with VCT and MRI, rats were anesthetized
with nitrous oxide, oxygen, and isoflurane as stated above.
Volumetric computed tomography. VCT imaging was performed
on a flat panel–equipped volumetric computed tomograph (Volume
CT, Siemens, Germany) on days 30, 40, 50, 60, and 70 after tumor
cell inoculation, with the following parameters: tube voltage 80 kV,
tube current 50 mA, scan time 51 seconds, rotation speed 10 seconds
(five rotations per scan), 120 frames per second, 512 × 512 matrix,
and 0.2-cm slice thickness. For each animal, contrast agent (1 g iodine
per kilogram; Imeron 400, Bracco, Milan, Italy) was injected intrave-
nously on day 70 after tumor cell inoculation during the second rota-
tion of the flat panel system (to acquire an unenhanced data set at first
for comparison with the contrast-enhanced data set). Reconstructions
of the images were done with VCT Reconstruction (kernel H80a,
Afra, Germany). Imaging data of the bone (VCT without contrast
agent) and the tumor vessels (VCT after contrast agent injection) in
those animals were reconstructed with Osirix (Osirix Dicom Viewer,
Version 2.7.5; The Osirix Foundation, Geneva, Switzerland). For com-
parison of vessel branching patterns between the groups, the number
of altered vessels (newly formed vessels or vessels showing an increase
in diameter) was counted in control and treated animals.
Magnetic resonance imaging. Magnetic resonance images were
acquired on a 1.5-T MR scanner (Symphony, Siemens, Germany)
on days 30, 40, 50, 60, and 70 after tumor cell inoculation (anesthe-
sia as given above) using a home-built coil for radiofrequency excita-
tion and detection, designed as a cylindrical volume resonator with
an inner diameter of 83 mm and a usable length of 120 mm [11].
The animals were imaged with T2-weighted turbo spin-echo se-
quences (orientation axial, TR 3240 milliseconds, TE 81 milliseconds,
matrix 152 × 256, FOV 90 × 53.4 mm2, slice thickness 1.5 mm,
number of slices 15, three averages, scan time 3 minutes 40 seconds;
orientation sagittal, TR 3240 milliseconds, TE 72 milliseconds, ma-
trix 108 × 256, FOV 150 × 63.3 mm2, slice thickness 2 mm,
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number of slices 10, three averages, scan time 2 minutes 40 seconds)
and a saturation recovery turbo flash sequence through the largest
diameter of the tumor (orientation axial, TR 373 milliseconds, TE
1.86 milliseconds, matrix 192 × 144, FOV 130 × 97.5 mm2, slice
thickness 5 mm, measurements 512, average 1, scan time 6 minutes
55 seconds) while 0.1 mmol/kg Gd-DTPA (Magnevist, Schering,
Germany) was infused over a period of 10 seconds. After the infu-
sion of the Gd-DTPA, signal intensity–time curves were recorded.
Analysis of the dynamic data was based on the pharmacokinetic
two-compartment model of Brix et al. [12]. In this model, compart-
ment 1 represents the intravascular volume and compartment 2 the
extravascular, extracellular space. The relative change in signal inten-
sity after contrast media infusion in these two compartments is
reflected by the amplitude A. Algorithms for calculation of the am-
plitude A were implemented in the computer-based software Dyna
Lab (Mevis Research, Bremen, Germany) [11,12]. With the aid of
this software tool, color maps of A were calculated on axial slices
showing the greatest extent of metastasis. After placing a region of
interest around the soft tissue metastasis on these color maps the
A values (arbitrary units) were determined.
The osteolytic lesion and the soft tissue tumor size were deter-
mined on unenhanced VCT and MR images by the cross product
of the length of the lesion in the direction of the affected bone
and its longest perpendicular diameter (in millimeters squared). Ac-
cording to the criteria for assessment of disease response in bone me-
tastases from the International Union Against Cancer (UICC), these
lesions were categorized as follows: complete response (disappearance
of all known lesions), partial response (at least 50% decrease in
size), no change (between 25% increase and 50% decrease in size),
and progressive disease (more than 50% increase in size) [13]. Mea-
surements of the bone metastases including osteolytic lesion size, soft
tissue tumor size, and amplitude A were done by two observers (T.B.
and S.B.) in consensus. Absolute values were recorded for the osteo-
lytic lesion and soft tissue tumor sizes (in millimeters squared) as well
as for the amplitude A in arbitrary units on days 30 to 70 after tumor
cell inoculation. Each of these absolute values was transferred into
percent of the value at day 30 (100%).
Anti-VEGF Antibody
The monoclonal anti-VEGF antibody bevacizumab (Avastin,
Roche, Basel, Switzerland) was administered (10 mg/kg IV) weekly
to the nude rats of the treatment group on days 35, 42, 49, 56, and
63 after tumor cell inoculation. Tumor-bearing control animals re-
ceived saline injections instead of bevacizumab.
Statistical Analyses
For each animal, the lesion sizes for osteolysis and soft tissue tu-
mor as well as the values for the amplitude A and the number of
altered vessels obtained from VCT and MR imaging were used to
draw a curve versus time after tumor cell inoculation. From these
numbers, relative values (%) were calculated referring to the initial
values on day 30 for each animal. For statistical comparisons, these
relative values were compared between the control and treatment
groups with the two-sided Wilcoxon test. P values < .05 were con-
sidered significant. For comparison between the numbers of animals
of each UICC category (progressive disease, no change, partial re-
sponse, complete response) the χ2 test was applied, considering
P values < .05 significant.
Bone Storage and Histology
Animals were sacrificed on day 70 after tumor cell inoculation. The
lower limbs from each animal were excised at sacrifice and the sur-
rounding tissue was stripped off. After fixation in 70% ethanol, the
specimens were decalcified in 10% buffered EDTA, pH 7.4, for
3 days. The specimens were cut parallel to the long axis, dehydrated
in a series of ethanol (70%, 80%, 90%, 100%) and xylene, and em-
bedded in paraffin wax by routine protocols. Sections of tissue blocks
(3 μm in thickness) were deparaffinized, rehydrated, and stained with
Mayer’s hematoxylin and eosin for histologic evaluation. Serial sections
were mounted onto coated SuperFrost Plus glass microscope slides
(Langenbeck, Germany) for further immunohistochemical analyses.
After being rinsed for 5 minutes with tap water for immunohisto-
chemical staining, the sections were rinsed several times with 0.1 M
PBS (pH 7.4) and incubated with 10% normal donkey serum (Vector,
Burlingame, CA) diluted in PBS for 2 hours. Thereafter, the sections
were incubated overnight with the antibody against rat CD31 (goat
polyclonal PECAM-1, Santa Cruz Biotechnology, Santa Cruz, CA),
which was diluted 1:100 in PBS containing 2% BSA. After several
rinses in PBS, sections were incubated for 2 hours with a 1:200 dilu-
tion of secondary antibody donkey anti–goat-Cy3 (Jackson Immuno-
research, Newmarket, UK) in PBS-BSA. The preparations were rinsed
again with PBS, counterstained using DAPI (Serva, Heidelberg, Ger-
many), dried, and coverslipped. Control sections were treated without
antibody, diluted and applied similarly to the specific antibody. Sections
were studied by fluorescence microscopy using a photomicroscope
equipped with epifluorescence (Axiophot; Zeiss, Jena, Germany).
Results
Imaging Osteolysis, Soft Tissue Tumor, and Vascularization
in Bone Metastasis
With the aid of VCT, all relevant skeletal structures of both rat
hind legs were imaged in high detail (Figure 1A). After injection of
contrast agent, the arterial branching pattern of the legs such as the
femoral, saphenous, and caudal femoral arteries as well as the plantar
vessels was demonstrated (Figure 1A). After inoculation of MDA-
MB-231 cells into the right superficial epigastric artery, bone me-
tastasis was observed exclusively at the right hind leg. By VCT
reconstruction, osteolyses became evident, such as that of the right
fibula shown in Figure 1A. After injection of CT contrast agent, new
vessel formation was visualized by VCT in the tumor-bearing leg
only. Typically, these vessels branched off the femoral, saphenous,
and caudal femoral arteries as shown in Figure 1A.
MRI revealed the surrounding soft tissue tumor, which usually ex-
ceeded the osteolytic lesion in size after intramedullar growth and pen-
etration of cortical bone (Figure 1B). Furthermore, anatomic structures
such as the pelvis, femur, tibia, and the surrounding muscles of the
thighs were well depicted at sufficient quality on the same MR image
(Figure 1B). In addition, the distribution of MR contrast agent was
shown on MRI color maps with the amplitude A representing the rela-
tive increase in signal intensity as a surrogate marker for vascularization,
which was expressed by the given color code as shown in Figure 1B. Low
values for contrast agent uptake were found in the muscles of the lower
extremities, the skin of the animal, and the bone marrow of the left hind
leg (Figure 1B). In this soft tissue tumor of the right hind leg especially
high values (color code, red) were displayed at the leading edge of the
tumor but not in the tumor center or the surrounding muscle tissue.
Histologic evaluation of this bone metastasis revealed highly vascularized
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tumor tissue at the leading edge of the tumor and poorly vascularized or
partly necrotic tissue in the center of the metastasis (data not shown).
Antiangiogenic Treatment with Bevacizumab
In this study, 17 control rats were compared with 15 rats treated
with the VEGF antibody bevacizumab (Table 1). By VCT and MR
imaging, the size of osteolytic lesions and soft tissue tumors as well
as the respective amplitude A in bone metastases were followed from
day 30 to day 70 after tumor cell inoculation (postinjection, p.i.) with
an interval of 10 days. In animals of the treatment group, bevacizumab
was injected weekly starting at day 35 until day 63 p.i. (Table 1).
According to the UICC criteria, treatment response of malignant
lesions in bone can be defined as progressive disease (PD), no change
(NC), and partial or complete remissions (PR and CR, respectively).
When these criteria were applied to the bone metastases in this study,
12 animals (70.6%) of the control group and 1 animal (6.7%) of the
treatment group showed progressive disease for their osteolytic le-
sions. In addition, 13 rats (76.5%) of the control group were diag-
nosed with a progressive soft tissue tumor compared with 3 animals
(20.0%) of the treatment group (Table 1). No complete response was
found after bevacizumab treatment. However, 8 (53.3%) and 6
(40.0%) rats experienced a partial remission or no change of osteo-
lytic lesions in response to bevacizumab compared with 2 (11.8%)
and 3 (17.6%) rats of the control group (P < .001, respectively). Sim-
ilarly, 10 (66.7%) and 2 (13.3%) rats underwent a partial remission
and no change, respectively, regarding their soft tissue tumor in re-
sponse to the treatment compared with 1 (5.9%) and 3 (17.6%) an-
imals of the control group, respectively (P < .001 for PR).
In control animals, the mean osteolytic lesion size increased con-
stantly from day 30 to day 70 p.i. by 135% (Figure 2A). In compar-
ison, this parameter increased only by 18% in the treatment group
from days 30 to 50 and decreased afterward to 81% at day 70 p.i.
Figure 1. Corresponding images of VCT reconstructions (A) and MRI sequences (B) of a rat hind leg bone metastasis. (A) VCT images
(upper row) of both hind legs illustrating the femur (F), tibia (T), and fibula (Fi). In the right hind leg, osteolytic destruction of the proximal
fibula (arrow) is seen (upper row, right). Contrast-enhanced VCT image of the left hind leg (lower row, left) visualizes the major vessels
such as the femoral artery (FA), saphenous artery (SA), caudal femoral artery (CFA), and plantar vessels. New vessel formation in the
bone metastasis is indicated by arrows (lower row, right). (B) Axial T2−weighted MR image (upper row) and DCE MRI parameter map of
the amplitude A (lower row) of a nude rat with arrowheads pointing to the femur (F), tibia (T), pelvis (P), skin (S), and muscles (M) and an
arrow pointing to the tumor. The color code for the parameter map is ranging from blue (low values) to red (high values).
Table 1. Design of Experiment and Treatment Results.
Animal No. Treatment Imaging No. (%) of Animals with Osteolysis Showing No. (%) of Animals with Soft Tissue Tumor Showing
PD NC* PR† T/C (%)‡ PD NC§ PR¶ T/C (%)‡
Control 17 0.9% NaCl# VCT, MRI** 12 (70.6) 3 (17.6) 2 (11.8) 100 13 (76.5) 3 (17.6) 1 (5.9) 100
Bevacizumab 15 10 mg/kg bevacizumab†† VCT, MRI** 1 (6.7) 6 (40.0) 8 (53.3) 35 3 (20.0) 2 (13.3) 10 (66.7) 27
PD, progressive disease; NC, no change; PR, partial response; for definitions, see the Materials and Methods section.
*χ2 test: PD versus NC, P = .0035.
†χ2 test: PD versus PR, P = .00043 (PD vs NC + PR, P = .00024).
‡Ratio between treatment (T ) and control (C ) values in percent at day 70 after tumor cell inoculation; the respective means are given in Figure 2, A and B.
§χ2 test: PD versus NC, P = .33016.
¶χ2 test: PD versus PR, P = .00023 (PD vs NC + PR, P = .00143).
#Administered on the same day and at the same volume as bevacizumab.
**At days 30 to 70 after tumor cell inoculation every 10 days.
††IV application on days 35, 42, 49, 56, and 63 after tumor cell inoculation.
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(P < .05 vs control, Figure 2A). The mean size of control soft tissue
tumors increased by 251% during the observation period, whereas
that of the treatment group decreased by 7% of the initial values
(P < .05 vs control, Figure 2B). The ratio between osteolytic lesion
and soft tissue tumor sizes increased in controls from 3.4 to 4.3
(days 30 to 70) but decreased from 4.1 to 2.0 in treated animals
(days 30 to 50) and increased thereafter to 3.1 (day 70 p.i.,
Figure 2C ). The mean value for amplitude A in bone metastases of
control rats remained almost constant (103% to 107%) during days
40 to 70 but decreased in the treatment group to 70% at day 70 p.i. of
its initial value (P < .05 for days 40 to 70, Figure 2D).
The typical progression of sham-treated bone metastasis within the
observation period (days 30 to 70) regarding osteolytic lesion devel-
opment and corresponding increase in soft tissue tumor is recorded
for an animal shown in Figure 3A (upper and middle rows). In these
growing lesions, the amplitude A values increased in area but not
Figure 2. Comparison of control (solid line) and treated animals (dashed line). Mean values in percent of the relative change in osteolytic
lesion size (A), soft tissue tumor size (B), and amplitude A values (D) versus time after tumor cell inoculation. (C) Ratio between size of
the soft tissue tumor and osteolysis over time. Error bars indicate the standard error and asterisks denote a significant difference be-
tween groups (P < .05).
Figure 3. Monitoring by VCT and MRI of a control rat (control, A) and two treated rats (Responsive and Nonresponsive, B and C, re-
spectively) at days 30, 50, and 70 after tumor cell inoculation. In the upper rows, osteolysis (arrows) of the right hind leg can be observed
on VCT images of bone reconstructions. On T2-weighted axial MR images (middle rows) the change in soft tissue tumors (arrows) is
shown over time. DCE MRI–derived parameter maps of the amplitude A are shown in the lower rows with values for A ranging from blue
(low) to red (high); bone metastases are indicated by arrows.
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in intensity as shown by the corresponding color maps (Figure 3A,
lower row). In a treated animal, a partial remission of the osteolytic
lesion and a corresponding decrease in the soft tissue tumor size was
paralleled by a distinct reduction in amplitude A values at days 50 and
70 p.i. (upper, middle, and lower row, respectively; Figure 3B). To
highlight both the most and the least intensive responses to treatment,
one of three animals showing “no change” regarding its osteolysis is
shown for comparison (upper row, Figure 3C ). Remarkably, such a
no-change status in the skeleton was in each case accompanied by a
progression of the corresponding soft tissue tumor (middle row,
Figure 3C ). The respective amplitude A values were in line with the
soft tissue tumor progression (lower row, Figure 3C ).
Contrast-Enhanced VCT and Histologic Examination
At the end of the experiment, a final contrast-enhanced VCT
was performed to image the arterial branching pattern of the tumor-
bearing hind legs. As shown in Figure 4A, new vessel formation and
change in vessel diameters as well as an altered branching pattern were
most prominent in control animals but almost absent in treated rats.
The mean number of newly formed vessels or vessels with an increased
diameter was 4.5 in the control and 2.5 in the treatment group (P <
.05, Figure 4B).
Histologic examination of the tumor-bearing leg in control rats
revealed bone metastasis with MDA-MB-231 tumor cells in the bone
marrow cavity stimulating osteolysis, infiltrating surrounding muscle
tissue, and inducing new vessel formation (Figure 5, A and C ). On
immunohistochemical sections, MDA-MB-231 tumor cells were
found within a tortuous network of tumor vessels (Figure 5E ). After
treatment with bevacizumab, new bone formation was found in the
bone marrow of these animals (Figure 5, B and D). In comparison to
sham-treated animals, only few viable tumor cells were left in the
bone marrow without prominent vascularization (Figure 5F ).
Figure 3. (continued)
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Discussion
Our aim was to evaluate treatment effects of the VEGF antibody
bevacizumab in an experimental model of breast cancer bone metas-
tasis. For this aim we imaged bone metastases by VCT and MRI to
assess osteolysis, corresponding soft tissue tumor, and angiogenesis in
these lesions of treated and control animals.
In most preclinical models of bone metastasis, either conventional
X-rays or optical imaging of luciferase activity is used as a fast and cost-
effective imaging method [14–16]. Optical imaging of bone metastasis
is used for early diagnosis and semiquantitative monitoring of relative
changes in soft tissue tumor size. A major drawback, however, is the
lack of exact anatomic information and the fact that light emission
from skeletal structures is influenced by the distance between the
light-emitting cell and surface of the animal, as well as by the scattering
caused by anatomic structures located in between. In contrast to op-
tical imaging, conventional X-rays visualize mainly the skeletal effects
elicited by bone-seeking tumor cells. Because only bone destruction of
more than 50% can be detected with this technique it is considered a
relatively insensitive measure of late skeletal changes [17]. Therefore,
new technologies are needed to assess early changes of bone destruc-
tion, such as VCT, which has been developed as a fast and high-
resolution imaging of anatomic structures in small animals [8]. For
example, bone structures in mice were recorded with a resolution
down to 200 μm [8,18]. Also, after contrast agent injection, tumor
vessels of a diameter as low as 50 μm were visualized in subcutaneous
tumors of mice [9]. Despite these qualities, a soft tissue tumor in the
vicinity of skeletal lesions can hardly be assessed except after using con-
trast agent. Without contrast agent, MRI has been shown to detect the
presence of a soft tissue tumor earlier than with X-rays [19]. Contrast-
enhanced MRI is beginning to be used in preclinical studies to non-
invasively image vascularization and treatment response by DCE MRI
[20]. In this regard, high and low amplitude A values as surrogate
markers for vascularization have been correlated to subcutaneous tu-
mors with highly and poorly vascularized tumor areas, respectively [11].
In this study, by VCTall relevant skeletal structures of the hind legs
and the extent of osteolysis could be followed during the observation
period three dimensionally and in high resolution. MRI showed the
anatomic location and extent of the soft tissue tumors, which clearly
exceeded the lytic bone lesions. DCE MRI according to the pharma-
cokinetic model of Brix et al. [12] was used to image and quantify the
distribution of contrast agent in bone metastasis. In these tumors, a
strong uptake of contrast agent indicating high vascularization was ob-
served. For these reasons, the combination of contrast-enhanced VCT
and MRI is highly suitable for preclinical treatment studies of bone
metastasis and in particular with antiangiogenic agents.
Treatment response to the anti-VEGF antibody bevacizumab was
therefore followed noninvasively by VCTand MRI in this study. The
amplitude A of DCE MRI in bone metastases remained largely un-
changed in control animals but decreased significantly in the treat-
ment group. This effect was paralleled by new bone formation and
decreasing tumor vascularization as shown by VCT and histology.
These results are in line with the findings of Kiessling et al., who
observed a decrease in amplitude A as well as in microvessel density
in subcutaneous heterotransplants of human skin squamous cell car-
cinomas after administration of a VEGF receptor antibody [21].
The assessment of disease response in patients with breast cancer
bone metastasis is widely quantified according to the criteria of the
UICC and the World Health Organization, which are based on plain
radiography and skeletal scintigraphy [13,22]. The RECIST (re-
sponse evaluation criteria for solid tumors) system, a more recent
classification of tumor response, considers bone metastases as “non-
measurable” [23]. In patients with bone metastases, DCE MRI was
shown to be valuable in the differentiation of benign and malignant
vertebral lesions [24]. In a small pilot study, signal-intensity curves
measured by MRI after contrast agent injection differed before and
after therapy with bisphosphonates and endocrine therapy in patients
responding to the treatment [25]. Therefore DCE MRI and, accord-
ing to the results of this study, the amplitude A can be considered a
Figure 4. Alteration of the vessel branching pattern in tumor-bearing hind legs at day 70 after tumor cell inoculation. (A) Contrast-
enhanced VCT images of tumor-bearing hind legs in two control (left column) and two treated (right column) rats. In tumor-bearing
control animals, new vessel formation (arrows) branching off the femoral (FA), saphenous (SA), and caudal femoral arteries (CFA) is
clearly present but almost absent in treated animals (arrows). (B) Mean number of altered vessels (newly formed vessels or vessels
showing an increase in diameter) in control (black column) and treated animals (white column). Error bars indicate the standard error
and the asterisk denotes a significant difference between the groups (P < .05).
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valuable imaging parameter for noninvasive monitoring of treatment
response in breast cancer bone metastasis.
Treatment with the VEGF antibody in nude rats caused partial
remission according to the UICC classification in up to 67% of
the animals, but had a different impact on osteolytic and soft tissue
lesions. As bone lysis is a relatively slow process, it can be assumed
that a treatment response is seen earlier in the soft tissue component
of the metastatic process. This might be the reason for the earlier
significant difference (day 40) in soft tissue metastasis between con-
trol and treated animals and the later treatment response (day 50)
regarding osteolysis. This relation is reflected by the ratio over time
between soft tissue and osteolytic lesion sizes, which indicates an early
decrease in soft tissue lesion size after application of bevacizumab and a
delayed treatment response of the osteolysis.
Our result that bone metastatic soft tissue tumors were reduced by
73% in comparison with control rats shows that this tumor entity
reacts similarly as reported for subcutaneous or orthotopically grow-
ing transplanted tumors. In fact, various studies reported growth
inhibition of human tumor xenografts of the breast, prostate, and
brain ranging from 25% to 95% after inhibition of VEGF with
bevacizumab [26]. Also, by a VEGF receptor-1–neutralizing anti-
body, the growth of human breast cancer MDA-MB-231 xenografts
was significantly suppressed [27].
Inhibition of bone resorption caused by antiangiogenic treatment
has been reported before when using the MDA-MB-231 model of
breast cancer bone metastasis [28,29]. These groups hypothesized a
direct inhibition of osteoclast activity and generation as causal factors
of the antiosteoclastic effect resulting from their antiangiogenic mole-
cules [28,29]. VEGF as one of the most import stimulators of angio-
genesis is known to increase osteoclast-mediated bone resorption, to
induce osteoclast chemotaxis, and to recruit osteoclasts to the site of
bone remodeling [30,31]. In histologic sections of breast cancer bone
metastasis of patients, the tumor cells strongly expressed VEGF and
the surrounding osteoclasts were positive for VEGF receptors [32]. In
the same study, peripheral blood mononuclear cells influenced by
VEGF and receptor activator of nuclear factor kappa B ligand differ-
entiated into osteoclast-like cells able to resorb bonelike substrate.
Therefore, VEGF is a promising factor to stimulate angiogenesis as
well as osteoclastic bone resorption. In line with this, the human
breast cancer cell line MDA-MB-231 was reported to express high
levels of VEGF-A and -B in bone and visceral metastasis [6]. Inter-
estingly, the expression of VEGF-A and -B mRNA as well as bone
resorption stimulators such as parathyroid hormone–related protein
and macrophage colony–stimulating factor mRNA was significantly
elevated in bone versus visceral metastasis [6]. There is evidence that
transforming growth factor beta, another key player in the pathogen-
esis of bone metastasis, is responsible for tumor secretion of VEGF in
breast cancer bone metastases [33,34].
Thus, several lines of evidence suggest that VEGF is associated
with the expression of major bone-resorbing factors in breast cancer
bone metastasis, such as transforming growth factor beta, parathyroid
hormone–related protein, macrophage colony–stimulating factor,
and nuclear factor kappa B ligand, and this association, in turn, high-
lights VEGF as an important osteolytic factor. Here we report that
bevacizumab, an antibody against all human isoforms of VEGF, re-
duced osteolysis by 19% of the initial pretreatment size and by 65%
compared to control animals. In 20% of the treated animals, soft tis-
sue tumors progressed, whereas an unchanged osteolytic lesion size
was observed. This observation fits well with the reported increased
presence of VEGF mRNA in skeletal compared to visceral metastasis.
In the rat model used, new bone formation was observed after
treatment with bevacizumab. This process requires VEGF for effec-
tive osteoblastic function [35]. It is plausible that two sources con-
tributed to VEGF levels in tumor-bearing rats: In addition to the
endogenous rat VEGF, human tumor cell–derived VEGF contributed
to the effect observed. The inhibition of this latter VEGF activity by
an antibody recognizing only human isoforms of VEGF has led to the
observed antitumor effect. It might be speculated, however, that addi-
tional inhibition of the rat isoforms would have resulted in an even
greater antitumor effect. In this regard, the model might have under-
estimated what could be possible in patients. Another aspect of the
animal model is as follows: By repeating VCT scans, tumor-bearing
rats were exposed to approximately 300 mGy (cumulative dose)
[36]. Although far from causing lethal (5 to 7.6 Gy) or other side ef-
fects typical for radiation, such as anemia, this dose could have exerted
a confounding therapeutic effect [37]. This is noteworthy in view of
the observation that bevacizumab in combination with irradiation can
elicit additive or even synergistic effects in treated patients [38].
Figure 5. Histological comparison between bone metastasis in
control (left column) and treated rats (right column). HE stain-
ing: highly vascularized (v, vessels) tumor (t) of MDA-MB-231
breast cancer cells infiltrating surrounding muscle tissue (m) (A).
MDA-MB-231 tumor cells (t) within bone marrow cavity after lysis
of cancellous bone (b, C). Osteogenesis in treated rats with re-
maining tumor cells (t) in between the newly formed bone (b, B
and D). Immunohistology: merging of blue, red, and green color
channels (green, MDA-MB-231 cells with GFP expression; blue,
DAPI staining; red, CD-31 staining) showing MDA-MB-231 cells
within a tortuous network of tumor vessels (E). Single remaining
MDA-MB-231 cells within newly formed bone (black). The re-
spective color channels (blue, red, and green) are shown below.
Magnifications: 5-fold (A and B), 10-fold (C and D), and 40-fold
(E and F).
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Bevacizumab monotherapy in patients with metastatic breast can-
cer has modest antitumor activity [39]. However, in phase 3 trials,
combination regiments of bevacizumab plus paclitaxel showed im-
proved response rates and significantly prolonged progression-free
survival as compared with paclitaxel alone [40,41]. So far, in patients
with breast cancer bone metastasis, a monotherapy with bevacizumab
has not been evaluated but appears to be a valuable treatment ap-
proach based on our results. As no complete remission was achieved
with bevacizumab alone in this study, combination therapies with
standard treatments for breast cancer bone metastasis such as chemo-
therapy, bisphosphonate therapy, and radiation therapy should be
evaluated in patients with breast cancer bone metastasis.
In conclusion, we report a promising treatment approach in breast
cancer bone metastasis with the VEGF antibody bevacizumab and
describe imaging methods of monitoring these lesions with VCT
and MRI. The combination of these methods in preclinical animal
models for investigation of antiangiogenic treatments was shown to
be highly suitable for monitoring all aspects of bone metastasis non-
invasively. Administration of the VEGF antibody bevacizumab re-
sulted in tumor response including inhibition of osteolysis of the
corresponding soft tissue tumor and of angiogenesis in a preclinical
model of breast cancer bone metastasis.
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